Cell Culture Monitoring Biosensor Market Forecast 2033

Technological Advancements in Biosensors and Rising Biopharmaceutical Production to Drive Cell Culture Monitoring Biosensor Market to USD 873.0 Mn by 2033 at 10.5% CAGR – Coherent Market Insights

The Global Cell Culture Monitoring Biosensor Market, by Product Type (Electrochemical Biosensors, Thermometric Biosensors, Fiber Optic Biosensors, Piezoelectric Biosensors, and Others), By End User (Pharmaceutical Industry, Biotechnology Organizations, and Research Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at USD 471.5 Mn in 2026 and is expected to exhibit a CAGR of 10.5% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Browse 28 Market Data Tables and 29 Figures spread through 164 Pages and in-depth TOC on The Global Cell Culture Monitoring Biosensors Market, by Product Type (Electrochemical Biosensors, Thermometric Biosensors, Fiber Optic Biosensors, Piezoelectric Biosensors, and Others), By End User (Pharmaceutical Industry, Biotechnology Organizations, and Research Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), - Forecast to 2033"

To know the latest trends and insights related to global cell culture monitoring biosensors market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cell-culture-monitoring-biosensor-market-219

Cell Culture Monitoring Biosensor Market - Driver

Expansion of Cell and Gene Therapy Manufacturing

The growing development and commercialization of cell and gene therapies are increasing demand for biosensors that continuously monitor cell viability, metabolism, nutrients, pH, dissolved oxygen, and culture consistency. For instance, in June 2026, the U.S. FDA approved Orca Bio’s Tregzi, an allogeneic regulatory T-cell-based immunotherapy for adults with hematological malignancies. Such approvals require scalable and tightly controlled cell-manufacturing processes, supporting the adoption of real-time cell culture monitoring biosensors. (Source: U.S.FDA)

Rising Adoption of Automated and Real-Time Cell Monitoring

Biopharmaceutical manufacturers are increasingly replacing manual sampling with in-line biosensors to reduce contamination risks, improve reproducibility, and optimize culture conditions. For instance, in March 2026, PHC Corporation launched LiCellGrow, which uses electrochemical in-line sensors to continuously measure glucose and lactate concentrations and automatically adjust culture-medium exchange. The launch demonstrates growing commercial demand for integrated biosensing and automated culture-control technologies. (Source: PHC Corporation)

Market Opportunity

Increasing Focus on Manufacturing Quality and Process Control

Stricter requirements for consistent product quality are encouraging manufacturers to monitor critical process parameters and critical quality attributes throughout cell cultivation. In May 2026, the FDA issued final guidance addressing chemistry, manufacturing, and controls for human cellular and gene therapy products. This regulatory focus is expected to encourage wider adoption of biosensors that provide continuous, traceable process data and support reliable scale-up and quality-by-design manufacturing. (Source: FDA)

Market Trends

Integration of Raman Biosensing with Machine Learning

Raman spectroscopy is increasingly being combined with machine-learning models to monitor several culture parameters simultaneously. A study published on June 29, 2026, demonstrated real-time monitoring of glucose, lactate, viable cell density, and antibody titre, with model accuracy exceeding an R² of 0.92. Automated glucose control increased product titre by up to 35% and reduced glycation by up to 27%.

Rising Adoption of Single-Use and cGMP-Compatible Sensors

The market is shifting toward pre-integrated, disposable sensor systems that reduce manual sampling and contamination risks. PHC’s 2026 LiCellGrow system uses single-use culture bags and in-line sensors to maintain closed, aseptic culture conditions. The company also announced plans to introduce pH and dissolved-oxygen monitoring units and cGMP-compatible consumables from late 2026 onward, supporting commercial cell-therapy production.

Growing Use of AI-Based Soft Sensors and Data Fusion

Manufacturers are developing software-based sensors that convert spectral and process data into estimated nutrient, metabolite, and cell-condition measurements. In July 2026, a New Biotechnology study evaluated Raman-data fusion and artificial neural networks for predicting arginine concentrations in monoclonal antibody-producing CHO cell cultures. This indicates growing interest in AI-enabled nutrient monitoring beyond conventional glucose and lactate measurements.

Expansion into 3D Cultures and Organ-on-Chip Platforms

Biosensors are increasingly being embedded into organoids and organ-on-chip systems for continuous, non-destructive monitoring. A Nature Portfolio review published on February 13, 2026, highlighted the integration of electrical, optical, mechanical, impedance, oxygen, and biochemical sensors into organ-on-chip platforms. These technologies support real-time evaluation of tissue function, barrier integrity, metabolic activity, and drug responses.

Key Takeaways of the Global Cell Culture Monitoring Biosensors Market

The global cell culture monitoring biosensors market is expected to exhibit a CAGR of 10.5% during the forecast period (2026-2033), owing to increasing cell culture applications in research and product development
Based on the product type, the electrochemical biosensors segment is expected to dominate the cell culture monitoring biosensor market with a 45.0% share in 2026. The segment benefits from rapid response, high sensitivity, low cost and ease of miniaturization for continuous metabolite and cell-condition monitoring. In February 2026, a peer-reviewed Biosensors study highlighted the analytical maturity and growing commercial scalability of electrochemical biosensors.
Based on End User, the pharmaceutical industry segment is projected to account for 52.0% of the market in 2026, supported by increasing biologics production, process-analytical-technology adoption and the need for real-time control of cell culture parameters. In January 2026, Genentech increased its investment in a North Carolina biomanufacturing facility to approximately USD 2 billion, incorporating advanced automation and digital tools to expand production capacity.
Based on the regional analysis, the North America is expected to lead the cell culture monitoring biosensor market with a 42.0% share in 2026, driven by its established biotechnology ecosystem, advanced biomanufacturing facilities and substantial pharmaceutical investments. Meanwhile, Asia Pacific is anticipated to be the fastest-growing region. In April 2026, India Pharma 2026 emphasized greater funding, infrastructure development and innovation in advanced therapeutics to strengthen the regional pharmaceutical and biopharma ecosystem.
Major players operating in the global cell culture monitoring biosensors market include C-CIT Sensors AG, Sarissa Biomedical Ltd, Lonza, Lifeonics ltd., Nova Biomedical, Cardea, Conductive Technologies Inc., and Bruker Corporation

Key Development

In March 2026, PHCbi, life sciences brand specializing in laboratory and medical equipment launched the LiCellGrow system for research use in Japan and selected international markets. Its electrochemical in-line sensors continuously measure glucose and lactate, providing real-time visibility into cellular metabolism. The platform automatically adjusts culture-medium exchange using the collected metabolic data, supporting closed, reproducible, and scalable cell-culture processes for cell and gene therapy development. (Source: PHC Holdings Corporation)
In July 2026, Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical launched xCELLigence RTCA eSight AI, an AI-powered software module for its real-time cell-analysis platform. The solution simplifies label-free imaging analysis by reducing manual cell-segmentation and parameter-adjustment requirements. Combining impedance-based biosensor measurements, live-cell imaging, and AI analysis can improve monitoring consistency and accelerate cell-based drug discovery and therapeutic-development workflows. (Source: Agilent Technologies)